Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-293.

Dong, Chen; Chen, Sung-Lang; Sung, Wen-Wei

Dong, Chen; Chen, Sung-Lang; Sung, Wen-Wei.

Dong C; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Chen SL; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Urology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Sung WW; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Urology, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. Electronic address: flutewayne@gmail.com.

Eur Urol ; 81(5): e123, 2022 05.

Article in English | MEDLINE | ID: covidwho-1936412

Subject(s)

Androgen Antagonists; COVID-19 Drug Treatment; Androgen Antagonists/therapeutic use; Clinical Trials, Phase II as Topic; Hormone Replacement Therapy; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Androgen Antagonists Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Eur Urol Year: 2022 Document Type: Article Affiliation country: J.eururo.2022.01.048

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google